Pon Doreen, Abe Andrew, Gupta Eric K
Department of Pharmacy Practice and Administration, College of Pharmacy, Western University of Health Sciences, 309 E. Second Street, Pomona, CA, 91766, USA,
Curr Atheroscler Rep. 2015;17(2):474. doi: 10.1007/s11883-014-0474-5.
Prostate cancer is the second most common cause of cancer and, when it metastasizes, has a high mortality rate. Statins may affect prostate cancer progression through cholesterol- and pleiotropic-mediated effects. The data on statin effects on prostate cancer has been mixed with benefit most likely occurring in reducing prostate cancer recurrence after radiation therapy and reduced mortality due to prostate cancer. More research is needed in this area to better characterize potential statin-mediated mechanisms that affect cancer. Also, future studies should report patients' anatomic/prognostic stage based on the updated staging system of the American Joint Committee on Cancer, which is a more effective predictor of recurrence and mortality than anatomic stage alone.
前列腺癌是第二大常见癌症，发生转移时死亡率很高。他汀类药物可能通过胆固醇介导效应和多效性效应影响前列腺癌的进展。关于他汀类药物对前列腺癌影响的数据并不一致，其益处最有可能体现在降低放疗后前列腺癌的复发率以及降低前列腺癌导致的死亡率方面。该领域需要更多研究，以更好地描述他汀类药物介导的影响癌症的潜在机制。此外，未来的研究应根据美国癌症联合委员会的更新分期系统报告患者的解剖学/预后分期，该系统比单独的解剖学分期更能有效预测复发和死亡率。
